 OUTLINE: This is a randomized, multicenter study. Patients are stratified according to Gleason score 7 or under vs over 7, T stage T1 or T2 vs T3 or T4, prostate-specific antigen level 20 ngmL or less vs greater than 20 ngmL, and lymph node involvement N0 vs N1 or N2. Patients are randomized to 1 of 2 treatment arms. 